About

Talee has developed a novel transgene and a number of innovations in multiple viral vectors that collectively will overcome challenges that have previously limited the clinical viability of gene therapy for cystic fibrosis. Currently, Talee has two proprietary technologies, an adeno-associated (AAV) viral gene therapy platform and a lentiviral gene therapy platform. Each has been developed to be highly tropic to human airway epithelia and, therefore, to overcome the biggest limitation to using gene therapy to treat or cure cystic fibrosis.